Schwabe Kaloba Pelargonium Cough and Cold Relief Tablets, 30 g

Product Information

The main characteristics of the eligible trials are shown in Table 1. All trials in AB had a randomized treatment phase of 7 days and used the BSS as the primary outcome measure for efficacy at day 7. Quality of life at day 7 was assessed by the EQ-5D-3L (adults) and the FGK (children and adolescents), respectively. One of the adult trials, study F, was a dose-finding trial. Among the pediatric trials, studies A and C included children and adolescents between 1 and 18 years of age, with dosage selection according to age. Study B was a dose-finding trial that included participants aged 6-18 years. For inclusion, pediatric and adult participants had to be suffering from symptoms of AB for a period not exceeding 48 hours and had to present with a BSS total score ≥5 points at screening. In the trials in CC, eligible patients had to be suffering from the primary symptoms nasal drainage and sore throat and from at least 1 (studies G and H) or 2 (studies I through K) of the secondary symptoms nasal congestion, sneezing, scratchy throat, hoarseness, cough, headache, muscle aches, and fever, or from 1 of the primary symptoms and at least 3 secondary symptoms. The time allowed between the onset of the first symptoms and study inclusion was 24-48 hours for studies G and H and up to 72 hours for studies I through K. All trials in CC had a randomized treatment phase of 10 days and applied the CIS at day 5 as the primary outcome measure for efficacy. Quality of life at day 5 was assessed by the EQ-5D-3L. Based on evidence and experience, the committee agreed that antibiotics should not routinely be offered to people (adults or children) with an acute cough associated with acute bronchitis. Antibiotics had a beneficial effect on some outcomes, but not others, and any benefit from antibiotics needs to be weighed up against their potential to cause adverse effects. Even where statistically significant effects were seen, these were often difficult to interpret and may not be clinically meaningful for many people. Individually, doxycycline compared with placebo showed a significant reduction in the following outcomes: mean number of days feeling ill, cough at follow-up and mean number of days of productive cough, where other antibiotics (amoxicillin and erythromycin) did not. Kaloba Pelargonium Cough & Cold Relief syrup is an orange to light brown syrup. However it is a natural product and therefore slight variations in colour and taste may occur. This product also contains the following ingredients:

Inhaled corticosteroids (fluticasone proprionate) significantly reduced the mean cough score by at least 50% reduction at the end the second week in non-smoking adults with acute or subacute respiratory tract infection compared with placebo (53.5% versus 80.5%; NNT 4 [range 3 to 13]; very low quality evidence). The mean difference in the average daily cough score in the second week in non-smoking adults was −0.9 (95% CI −1.3 to −0.4; very low quality evidence). There was no difference in smokers. One RCT found that additional treatment sought after 2 weeks of study treatment was significantly lower with fluticasone proprionate compared with placebo (43.1% versus 62.7%, NNT 6 [range 3 to 35]; very low quality evidence). It’s important to continue treatment for 3 days after symptoms have resolved to prevent a relapse. Pelargonium safety Antibiotics (erythromycin, cefuroxime or doxycycline) were significantly better than placebo for improving abnormal lung examination at follow-up in adults with acute bronchitis (5 RCTs, n=613, 18.5% versus 34.8%, NNT 7 [5 to 11]; moderate quality evidence). However, only 1 RCT in this analysis of cefuroxime versus placebo (accounting for 77.8% of the weight) had a significant reduction for this outcome in the antibiotic group.Trials A through C performed in the indication AB included a total of 719 children and adolescents, 412 of whom received EPs 7630. Cough intensity at baseline was comparable for EPs 7630 and placebo, with a meta-analysis difference of 0.04 points; 95% confidence interval, 95% CI: -0.04, 0.13 points on a 5- point scale. The main results of the meta-analysis for change in cough intensity between baseline and day 7 are shown in Figure 2. The reduction in cough intensity was significantly more pronounced in participants randomized to EPs 7630 across all trials (point estimate for difference: 0.6 points) as well as in the single trials A, C, and in the 3 x 30 mg/d group of trial B. Substantial heterogeneity between the trials was attributable to differences between the effect sizes for the individual treatment comparisons - all of which favored EPs 7630 - and not differences regarding the direction of the effect. Confidence intervals for the point estimates in trial B were wider than those for trials A and C because the placebo group of trial B had to be split to enable the comparison for the two different dosages of EPs 7630. Across all trials, 328/412 (79.6%) children and adolescents treated with EPs 7630 and 126/307 (41.0%) in the placebo group showed a reduction in the cough intensity score by at least 50% of the baseline value [meta-analysis rate/risk ratio (RR), EPs 7630 / placebo: 1.86; 95% CI: 1.34, 2.59], and 74/412 (18.0%) and 17/307 (5.5%) presented with complete remission of cough (RR: 2.91; 95% CI: 1.26, 6.72). The safety of this plant remedy is still not thoroughly tested. Generally, known side effects of Pelargonium sidoides include heartburn, nausea, worsening respiratory symptoms and stomach upset. Drug Interaction Dextromethorphan was no more effective than placebo (in 4 RCTs) or diphenhydramine (in 1 RCT) in reducing various cough outcomes in children with an acute cough, a night cough or an upper respiratory tract infection (very low quality evidence). In 2 RCTs, there were no differences between the groups in adverse effects, which were generally mild. In another RCT, adverse events (mainly gastrointestinal and dizziness) were reported in 34% of the dextromethorphan group and 5% of the placebo group (p value not reported). Paul IM, Yoder KE, Crowell KR, et al. Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics. 2004;114(1):e85-e90.

Antibiotics (erythromycin, cefuroxime, doxycycline or co-amoxiclav) did not significantly reduce the number of adults and children with acute bronchitis without improvement at physician follow-up compared with placebo (very low quality evidence). When a subgroup of people with non-purulent tracheo-bronchitis from an upper respiratory tract infection study was omitted, antibiotics were significantly better than placebo (5 RCTs, n=816, 7.7% versus 17.6%; NNT 11 [7 to 19]; moderate quality evidence). However, only 1 RCT in this analysis of cefuroxime versus placebo (accounting for 35.5% of the weight in the meta‑analysis) showed a significant improvement compared with placebo. Due to its anti-bacterial and immune-modulating characteristics Pelargonium appears to be a good alternative to the conventional therapy of treating respiratory illnesses with antibiotics. Presentations connected with ARTIs commonly overlap [ 10], and for AB and CC, for example, it was even suggested that both terms may describe different aspects of the same syndrome [ 6]. CC is characterized by rhinorrhea, sore throat, sneezing, chilliness, and mainly dry cough. In AB, cough is the prominent symptom, typically dry during the initial 2-3 days, then productive for up to 2 weeks, and then again dry, sometimes lasting for several weeks [ 6, 11]. In CC, however, mucus hypersecretion may also occur during the first 2-3 days [ 6], and coughing may be provoked by postnasal drip as well [ 12, 13]. It is therefore increasingly recognized that distinguishing between cough associated with AB or CC may hardly be practicable [ 6, 14], especially since the implications of the distinction for disease management are minimal and treatment is often initiated in practice based on clinical symptoms alone and without establishing a specific diagnosis [ 15].Based on Oduwole et al. (2014), a systematic review and meta-analysis including 3 randomised controlled trials (RCTs) in 568 children and young people (aged 1 to 17 years) with acute cough caused by an upper respiratory tract infection. A. Geranium tea is also known as pelargonium sidoides tea. You can prepare it using dried or fresh leaves of the herb pelargonium sidoides.